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ABSTRACT 23 
 24 
Mycobacterium abscessus is responsible for a wide spectrum of clinical syndromes and is 25 
one of the most intrinsically drug-resistant mycobacterial species. Recent evaluation of the 26 
in vivo therapeutic efficacy of the few potentially active antibiotics against M. abscessus was 27 
essentially performed using immune-compromised mice. Herein, we assessed the feasibility 28 
and sensitivity of fluorescence imaging for monitoring the in vivo activity of drugs against 29 
acute M. abscessus infection using zebrafish embryos. A protocol was developed where 30 
clarithromycin and imipenem were directly added to water containing fluorescent M. 31 
abscessus-infected embryos in a 96-well plate format. The status of the infection with 32 
increasing drug concentrations was visualized on a spatiotemporal level. Drug efficacy was 33 
assessed quantitatively by measuring the index of protection, the bacterial burden (CFU) and 34 
the number of abscesses through fluorescence measurements. Both drugs were active in 35 
infected embryos and were capable of significantly increasing embryo survival in a dose-36 
dependent manner. Protection from bacterial killing correlated with restricted mycobacterial 37 
growth in the drug-treated larvae and with reduced pathophysiological symptoms, such as 38 
the number of abscesses within the brain. In conclusion, we present here a new and efficient 39 
method for testing and compare the in vivo activity of two clinically-relevant drugs based on 40 
a fluorescent reporter strain in zebrafish embryos. This approach could be used for rapid 41 
determination of in vivo drug susceptibility profile of clinical isolates and to assess the 42 
preclinical efficacy of new compounds against M. abscessus. 43 
44 
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INTRODUCTION 45 
 46 
The emerging pathogen M. abscessus (Mabs) is the etiological agent of a wide spectrum 47 
of infections in humans including severe chronic pulmonary and disseminated infections, 48 
mostly in immunosuppressed and in cystic fibrosis (CF) patients (1), and cutaneous diseases, 49 
often post-traumatic and post-surgical. This neglected pathogen causes a higher fatality rate 50 
than other Rapidly Growing Mycobacteria (RGM) and CF patients infections is becoming a 51 
major threat in most CF centers worldwide (2). Mabs infections occur in early childhood (3), 52 
are severe and sometimes fatal, especially following transplantation (4-6), and may lead to 53 
outbreaks of infection (6). It is also the main RGM responsible for nosocomial and iatrogenic 54 
infections in humans (post-injection abscesses, cardiac surgery, and plastic surgery) (7-9). It 55 
has been reported to cross the blood-brain barrier and cause important central nervous 56 
system (CNS) lesions. Although rapid grower, Mabs possesses several important pathogenic 57 
traits such as the ability to i) persist silently for years and even decades (10) in the human 58 
host, and to ii) induce lung disease with caseous lesions and granuloma formation in the 59 
parenchyma (11, 12).  60 
The major issue with Mabs relies on its intrinsic resistance to the most available 61 
antibiotics. The American Thoracic Society has recommended different groups of agents, 62 
namely macrolides (clarithromycin), aminoglycosides (amikacin), cephamycins (cefoxitin) 63 
and carbapenems (imipenem) to treat Mabs infections (13). Patients with severe infections 64 
are generally treated with long courses of combinatorial antibiotic therapy, often backed by 65 
surgical resection. As antibiotic susceptibility testing is not fully standardized, the clinical 66 
response to drugs does not correlate well with in vitro susceptibility tests and failure occurs 67 
frequently despite administration of two or three antibiotics for several months (14). This 68 
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further emphasizes the need for suitable animal models (15, 16). In addition, different 69 
clinical isolates of this emerging pathogen are not uniformly susceptible to currently used 70 
antibiotics (17). As a consequence, an optimal regimen to cure the Mabs infections has not 71 
been yet established. 72 
Thanks to the recent availability of efficient genetic tools (18), Mabs has been proposed 73 
as an attractive experimental model to study non-tuberculous mycobacteria associated 74 
diseases. Our poor understanding of the pathogenesis of Mabs, essentially hampered by the 75 
restricted panel of cellular/animal models available, prompted us to develop the zebrafish 76 
(ZF) model of infection evaluate Mabs infections (19). In particular, the Mabs/zebrafish 77 
model already provided important insights into Mabs pathogenesis including the unexpected 78 
CNS tropism, a finding relevant in the light of recent clinical studies reporting the presence 79 
of Mabs in the CNS of infected human patients (20, 21). Since infection foci/abscesses within 80 
the CNS, particularly the brain, appear very rapidly and are easily visualized, we reasoned 81 
that this alternative model could represent a valuable and cheap system to evaluate and 82 
compare the in vitro and in vivo activity of drugs against Mabs. Such a simple and innovative 83 
system would be particularly suited to screen active molecules and/or assess antibacterial 84 
activities for the discovery of the urgently needed drugs to fight Mabs.  85 
Here, we report experimental conditions for spatiotemporal in vivo imaging of Mabs 86 
infections and their use to test the efficacy of drug treatments. This represents a unique 87 
biological model allowing non-invasive observations to evaluate, in real time, the efficacy of 88 
antibiotics in living infected vertebrates, a system that could be applied to high-throughput 89 
in vivo testing of drug efficacy against the most drug-resistant mycobacterial species. 90 
91 
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MATERIALS AND METHODS 92 
 93 
M. abscessus strains and growth conditions 94 
The rough variant of M. abscessus sensu stricto strain CIP104536
T
 (ATCC19977T) (R-95 
Mabs) was grown at 30°C in Middlebrook 7H9 broth supplemented with 10% Oleic 96 
acid/Albumin/Dextrose/Catalase (OADC) enrichment and 0.05% Tween 80 (7H9
T
) or on 97 
Middlebrook 7H10 agar containing 10% OADC (7H10). Recombinant Mabs carrying pTEC27 98 
(Addgene, plasmid 30182) that allows to express the tdTomato fluorescent protein under 99 
the control of a strong mycobacterial promoter were grown in the presence of hygromycin 100 
500 mg/L (19). 101 
 102 
Mice experiments and CFU counting 103 
6-8 weeks old BALB/c mice were divided in groups of 5-7 mice and used for either 104 
intravenous (i.v.) or aerosol challenges. Inocula were prepared from rapidly thawed frozen 105 
aliquots, and bacterial clumps were eliminated by iterative passages through a 29.5-gauge 106 
insulin needle (Becton Dickinson). Bacterial suspensions were then diluted in phosphate 107 
buffer saline (PBS). For i.v. inoculations, 10
6
 CFU (in 200 µl) were injected into the lateral 108 
tail/caudal vein, as previously described (22, 23). Pulmonary infections were achieved with 109 
aerosolized Mabs using an aerosol generator, equipped with a Micro Mist
®
 small volume 110 
nebulizer (Hudson RCI-Teleflex medical) containing 6 ml of bacterial solution at 4 × 10
7
 111 
CFU/ml. Pre-sleeping mice (isoflurane® Abbott) were anesthetized with 200 µl of 112 
Hypnomidate (Etomidate®, Janssen-Cilag) and placed into an opened 50 ml syringe fixed on 113 
the top of a closed compartment containing the nebulizer. In this device, nebulization lasted 114 
for 15 min to vaporize the entire bacterial suspension. Lungs, liver and spleen were collected 115 
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in PBS, crushed and 10-fols serial dilutions were plated on Middlebrook 7H11 plates for CFU 116 
counting, as previously described (22, 23). Plates were then incubated at 37°C for up to 7 117 
days. The results were expressed as the mean Log10 CFU per organ.  118 
 119 
Minimal inhibitory concentrations 120 
Antibiotics powder tested in drug susceptibility assays were pharmaceutical standards 121 
for imipenem/cilastatin (Mylan) or clarithromycin (Sigma-Aldrich). Stock solutions were 122 
dissolved in water (imipenem) or in DMSO (clarithromycin). Drug susceptibility testing was 123 
also determined using the microdilution method, in cation-adjusted Mueller-Hinton broth, 124 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (24). In 125 
addition, the susceptibility profile was also determined on LB agar supplemented with 126 
increasing concentrations of compounds. Serial 10-fold dilutions of each actively growing 127 
culture were plated and incubated at 37°C for 3-4 days and the MIC was defined as the 128 
minimum concentration required to inhibiting 99% of the growth. 129 
 130 
Zebrafish care and ethic statements 131 
All zebrafish experiments were done at the University Montpellier 2, according to 132 
European Union guidelines for handling of laboratory animals 133 
(http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm) and approved by 134 
the Direction Sanitaire et Vétérinaire de l'Hérault and Comité d'Ethique pour 135 
l'Expérimentation Animale de la région Languedoc Roussillon (CEEA-LR) under the reference 136 
CEEA-LR-13007. Experiments were done using the golden ZF mutant (25), maintained as 137 
described earlier (19). Ages of embryos are expressed as hours post fertilization (hpf). 138 
 139 
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Microinjection of M. abscessus into embryos 140 
Mid-log phase cultures of Mabs expressing tdTomato were centrifuged, washed and 141 
resuspended in PBS supplemented with 0.05% Tween-80 (PBS
T
). Bacterial suspensions were 142 
then homogenized through a 26-gauge needle and sonicated and the remaining clumps were 143 
allowed to settle down to for 5-10 min, as previously described (19). Bacteria were 144 
concentrated to an OD600 of 1 in PBS
T
 and i.v. injected (у2nL containing 300 CFU) into the 145 
caudal vein in 30hpf embryos previously dechorionated and anesthetized. To follow 146 
infection kinetics and embryo survival, infected larvae were transferred into 96 well plates (2 147 
embryos/plate) and incubated at 28.5°C. The inoculum size was checked by injection of 2nL 148 
in sterile PBS
T
 and plated on 7H10 supplemented with hygromycin 500 mg/L.  149 
 150 
Drug efficacy assessment in Mabs-infected ZF 151 
Clarythromycin and imipenem/cilastatin were added at one day post-infection (dpi), 152 
directly into the water containing the embryos. Three doses were tested, corresponding to 153 
1.7X, 17X and 170X the MIC of clarithromycin and 0.5X, 5X or 28X the MIC of imipenem, 154 
based on the values determined using the microdilution method (Table S1). In vivo drug 155 
efficacy was determined for each concentration by following i) bacterial burdens, ii) kinetics 156 
of embryo survival, iii) evolution of the infection foci/abscesses within the CNS and iv) effect 157 
on bacterial cord formation/reduction. Survival curves were determined by recording dead 158 
embryos (no heartbeat) every day for up to 13 days. Regarding the kinetic of mycobacterial 159 
loads, groups of three infected embryos were collected, lysed individually in 2% Triton X100- 160 
PBS
T
 with a 26-gauge needle and resuspended in PBS
T
. Several 10-fold dilutions of 161 
homogenates were plated on 7H10, the appropriate antibiotics and added of mix of BBL
TM
 162 
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MGIT
TM
 PANTA
TM
 (Becton-Dickinson) using as recommended by the supplier. CFU were 163 
enumerated after 4 days of incubation at 30°C. This procedure was repeated at 0, 3, 5 dpi.   164 
 165 
Microscopy 166 
Widefield bright-field and fluorescence live microscopy of infected embryos were 167 
performed using an Olympus MVX10 epifluorescent microscope equipped with a X-168 
Cite
®
120Q (Lumen Dynamics) 120W mercury light source. Images are acquired with a digital 169 
color camera (Olympus XC50) and processed using CellSens software (Olympus). 170 
Fluorescence filter cube TRITC-MVX10 is used for detection of red light. For live imaging, 171 
anesthetized infected embryos were positioned in dishes and immobilized with 1% low-172 
melting point agarose solution covering the entire larvae then immobilized embryos are 173 
immersed with fish water containing tricaine for direct visualization. 174 
 175 
Image Processing and Analysis 176 
Final images analysis and visualization are performed using GIMP 2.6 freeware to merge 177 
fluorescent and DIC images and to adjust levels and brightness and to remove out-of-focus 178 
background fluorescence. 179 
 180 
Statistical Analyses 181 
Statistical analyses of comparisons between Kaplan-Meier survival curves were 182 
performed using the log rank test with Prism 4.0 (Graphpad, Inc). CFU counts and 183 
quantifications experiments were analyzed using one-way ANOVA and Fishers exact test, 184 
respectively. Statistical significance was assumed at p values <0.05.  185 
 186 
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RESULTS 187 
M. abscessus fails to establish a persistent infection in BALB/c mice 188 
Experiments were first aimed at determining the colonization rate of R-Mabs in a murine 189 
pulmonary infection model (Figure 1A). Aerosol infections of BALB/c mice led to an initial and 190 
rapid increase of the bacterial burden from 1-3 days post-infection (dpi) in the lungs, followed 191 
by a phase of infection control leading to a reduction (starting after 3dpi) and almost 192 
complete clearance of the bacilli at 27dpi. Very few bacteria were detected within the spleen 193 
or the liver of infected mice. The colonization profile after i.v. challenge showed that bacilli 194 
were primarily found in the liver at 1dpi and to a lesser extent in the spleen and lungs (Figure 195 
1B). All heavily infected organs rapidly underwent a progressive reduction in bacterial loads 196 
with a 3-Log10 CFU decrease in the liver and lungs at 30dpi, highlighting a transient 197 
colonization process. This indicates that immune-competent mice steadily eradicate the 198 
pathogen and therefore that wild-type BALB/c mice are not well adapted to investigate the in 199 
vivo efficacy of therapeutic treatments. This would require testing a very large number of 200 
animals to insure that the observed CFU decrease results from an antibiotic regimen rather 201 
than from the natural course of infection. This highlights the need of an alternative animal 202 
model, susceptible to Mabs infection, permissive to bacterial replication and leading to the 203 
development of infection foci/abscesses and death. Therefore, the ZF embryo model was 204 
chosen to test in vivo assessments of drugs against Mabs. 205 
 206 
Zebrafish larvae for in vivo assessment of drug activity in M. abscessus 207 
An experimental protocol was designed to assess in vivo antimycobacterial drug activity 208 
against Mabs in ZF larvae (Figure 2). Red fluorescent tdTomato-expressing R-Mabs were 209 
injected in the caudal vein of embryos at 30 hours post-fertilization (hpf) and transferred 210 
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into 96-well plates. Antibiotics were directly added at 1dpi to the water containing the 211 
infected embryos and the drug-supplemented water was then changed on a daily basis for 5 212 
days. Thanks to the optical transparency of the embryos, daily microscopic recording of 213 
mortality (transmission) as well as bacterial burden (fluorescence) were used as phenotypic 214 
read-outs. We have previously shown that the rough Mabs exhibits a marked neurotropism 215 
with massive abscesses within the CNS (19), thus prompting us to assess the 216 
chemotherapeutic activity of drugs in Mabs-infected embryos with a special emphasis on 217 
infection within the CNS (Figure 2). Drug-mediated toxicity was investigated by checking 218 
survival curves of non-infected embryos treated with increasing drug doses.  219 
 220 
Minimal inhibitory concentrations of antimycobacterial drugs against M. abscessus 221 
 We first determined the in vitro activity of various drugs, including antitubercular 222 
agents, against Mabs using microdilution in cation-adjusted Mueller-Hinton broth, according 223 
to the Clinical and Laboratory Standards Institute guidelines (24). Table S1 shows that the 224 
activity varies considerably, in agreement with other studies (17). The first-line 225 
antitubercular drug isoniazid and second-line drug thiacetazone appeared inactive against 226 
Mabs. Among the few clinically used drugs for the treatment of Mabs infection, cefoxitin, 227 
amikacin, imipenem and erythromycin exhibit moderate activity in vitro on agar plates with 228 
MICs ranging from 60-125 µM, whereas clarithromycin demonstrated the highest activity 229 
with an MIC value of 4 µM. Because clarithromycin and imipenem exhibit different 230 
physicochemical properties (high molecular weight and hydrophobicity for clarithromycin 231 
versus low molecular weight and hydrophilicity for imipenem), they were further 232 
investigated for their in vivo therapeutic efficacy in Mabs-infected ZF. 233 
 234 
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In vivo susceptibility of M. abscessus to clarithromycin 235 
Due to poor information concerning the mechanisms of drug uptake by ZF 236 
embryos/larvae, we tested a wide range of clarithromycin concentrations: 6.6 µM to 668 µM 237 
(1.7X to 170X the in vitro MIC value from the microdilution method). Supplementing the 238 
embryo-containing water with low or intermediate doses (1.7X and 17X the MIC, 239 
respectively) led to no toxicity as measured by larval survival, while the highest tested dose 240 
(170X MIC), led to a 10% reduction in larval survival at 9dpi, with respect to the control 241 
group (water with 1% DMSO; Figure 3A) (26). In the presence of high doses of 242 
clarithromycin, embryos had a curved body trunk with un-inflated swim bladder (Figure 3A, 243 
inset). These phenotypic alterations were hardly observed when exposed to intermediate or 244 
low doses of clarithromycin (not shown).  245 
No significant increased survival was found when infected-embryos were exposed to 246 
low and intermediate drug concentrations (Figure 3B). In contrast, high doses extended the 247 
life span of infected embryos and fully protected the infected embryos up to 9dpi, when the 248 
first embryo started to dye, which coincidently, corresponded to the toxicity-induced-killing 249 
effect (Figure 3A). This shows that clarithromycin, using the highest regimen, is efficient in 250 
the ZF test system. 251 
 252 
Effects of clarithromycin on ZF survival, bacterial burden and abscesses 253 
Increased survival was associated with lower bacterial burdens after 3dpi in the 254 
presence of the highest dose (170X MIC), as determined quantitatively by CFU plating 255 
(Figure 3C), whereas treatment with the low or intermediate doses failed to restrict 256 
mycobacterial growth. In vivo drug efficacy was next monitored by time-lapse fluorescence 257 
microscopy (Figure 3D) of the rapidly growing infection foci and abscesses in the larval brain 258 
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(19). Imaging the same infected embryos at 3 and 5dpi revealed that abscesses within the 259 
brain were already reduced at 3dpi when treated with high drug concentrations and this 260 
reduction of the clinical signs of infection was even more accentuated at 5dpi. Consistent 261 
with the survival curves and kinetic of bacterial growth, there was no visible reduction of the 262 
infection at 5dpi in ZF treated with low or intermediate drug concentrations. Quantitative 263 
analysis reveals that high doses of clarithromycin reduced by 50% the number of embryos 264 
with abscesses (Figure 3E) both in the brain and the spinal cord (Figure 3F). This indicates 265 
that clarithromycin exerts a therapeutic effect by inhibiting mycobacterial growth, 266 
preventing the development of abscesses within the CNS and protecting the embryos from 267 
bacterial killing. 268 
 269 
Effects of imipenem on ZF survival and reduction of the pathological signs 270 
Imipenem is a clinically relevant drug against Mabs known to act on L, D-transpeptidases 271 
(17, 27). Concentrations from 0.5X to 28X MIC of imipenem were tested, which all fail to 272 
display signs of toxicity-induced-killing or developmental abnormalities (data not shown). 273 
When assessing the effect of imipenem on infected ZF, no increased survival was found with 274 
low drug concentrations. However, treatment with intermediate doses led to a significant 275 
increase in survival and 100% of protection was observed in the presence of the highest drug 276 
concentration (Figure 4A). These survival rates correlated with CFU loads as intermediate 277 
and high doses of imipenem started to restrict bacterial growth at 3dpi (after two days of 278 
drug treatment) (Figure 4B). With the highest dose, there was a 3 Log10 decrease in CFU at 279 
5dpi (four days of treatment) compared with the untreated control group. Time-lapse 280 
fluorescence microscopy further confirmed the in vivo efficacy of imipenem at intermediate 281 
and high doses, illustrating the inhibition of bacterial growth and disappearance of abscesses 282 
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in the larval brain at 3 and 5dpi, respectively (Figure 4C). High doses significantly reduced the 283 
proportion of embryos with abscesses (Figure 4D), a phenotypic effect that was particularly 284 
apparent in the brain on infected embryos (Figure 4E), indicating that imipenem reduces the 285 
pathology signs of the infection. 286 
These results prompted us to check whether imipenem can counteract/alter the 287 
progression of an already established infection, if given at 3dpi when brain abscesses are 288 
already apparent (Figure S1A). Death curves indicate that treatment with high doses of 289 
imipenem efficiently extended the life span of embryos with pre-existing abscesses (Figure 290 
S1B). A large proportion (more than 60%) of the treated embryos survived to the infection 291 
compared to 10% for the non-treated individuals (p=0.008). The 40% embryos that died 292 
despite treatment showed increased bacterial loads in the CNS (data not shown). The 293 
increased index of protection rate was associated to a significant decrease in the number of 294 
embryos with abscesses (Figure S1C), particularly within the brain (Figure S1D). This 295 
curative protocol shows that imipenem was able to cure embryos with pre-existing 296 
abscesses and protect severely infected ZF.  297 
 298 
In vivo inhibition activity of imipenem on mycobacterial cording 299 
Rough Mabs displays a dry texture with organized serpentine cords on agar plates (19, 300 
28, 29) and large bacterial clumps consisting mainly of cords in liquid cultures (19). Our 301 
recent studies also unraveled the presence of serpentine cords within the brain or spinal 302 
cord of embryos infected with the rough morphotype and emphasized the role of cording in 303 
immune evasion by preventing phagocytosis of Mabs by macrophages and neutrophils (19). 304 
Cords are easily visualized and counted by fluorescence microscopy (Figure 5A), and they 305 
promote extracellular replication, abscess formation and tissue damage (19). We checked 306 
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whether exposure of infected embryos to imipenem may affect the development of 307 
mycobacterial cords. Figure 5B shows the impact of imipenem treatment on the number of 308 
cords; quantitative analysis is shown in Figure 5C. The presence of low doses of imipenem 309 
has little impact on mycobacterial cords, although a reduction of the number of embryos 310 
with cords was detected at 4dpi. However, this effect was more pronounced with higher 311 
drug concentrations with only 20% of cord-laden embryos at 4dpi (compared to 60% for 312 
untreated embryos at 4dpi). This dose-dependent effect occurred essentially within the CNS 313 
whilst reduction of cord formation within the vasculature was not significant (Figure 5D).  314 
315 
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DISCUSSION 316 
At a basic research level, the appropriate use of animal models can help to improve our 317 
understanding of host-pathogen interactions. At a more applied level, preclinical evaluation 318 
of new drugs requires in vivo testing prior to progressing along the development pipeline. 319 
However, in vivo animal studies, when possible, are usually costly and time-consuming and 320 
present a major bottleneck in drug developments. Implementation of novel approaches, 321 
expected to accelerate the in vivo assessment of drugs, is particularly justified in two cases. 322 
First, such systems are useful for bacterial infections requiring extended periods of drug 323 
treatment such as mice infected with M. tuberculosis, for which rapid in vivo assessment of 324 
drug efficacy directly in infected mice using fluorescence imaging (30) or using improved 325 
firefly luciferase (31) were elegantly demonstrated. We similarly show in this study how the 326 
use of fluorescence imaging can be useful in evaluating antimicrobial activity against Mabs. 327 
Second, alternative biological systems are particularly relevant for infections lacking of a 328 
permissive animal model. In this context, we recently demonstrated the high susceptibility of 329 
ZF embryos to Mabs (19) and how the number of CNS abscesses may represent a marker for 330 
establishing in vivo antibiotic activity against Mabs.   331 
One of the key steps of drug discovery process is to identify and evaluate the in vitro and 332 
in vivo potential of new hits against Mabs using adapted animal models. The murine model 333 
in immune-competent BALB/c mice (i.v. or aerosol infections), led only to transient 334 
colonization, impeding its use as a valuable animal model for drug testing. Comparatively, 335 
SCID mouse model has been shown to produce a chronic infection of Mabs, but this model 336 
has not been used for drug testing (29, 32). Granulocyte-macrophage colony-stimulating 337 
(GM-CSF) knockout mice have recently been used to develop a new animal model of 338 
persistent pulmonary Mabs infection that can be used for preclinical efficacy testing of anti-339 
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microbial drugs (15). Azithromycin treatment of Mabs-infected GM-CSF KO mice resulted in 340 
a lower bacterial burden in the lungs and spleen, weight gain and significant improvement in 341 
lung pathology (15). Another report proposed Nude mice as an adequate model for in vivo 342 
chemotherapy studies (16). However, both models raised the question of the adaptive 343 
response in addition to the antibiotic activity in eradicating the bacilli. It was previously 344 
shown that, albeit being a rapid-growing mycobacterium, Mabs infection was only controlled 345 
in mice with a functional adaptive immune response (22), as compared to M. chelonae, 346 
which was cleared even in T cell-deficient mice. Despite the fact that both immune-347 
compromised mice present a significant advance as compared to wild-type mice in 348 
preclinical assessments, these models remain costly, time-consuming and, most likely, not 349 
suitable for a general use in drug screening strategies.  350 
New non-mammalian models of infection have been developed, including Drosophila 351 
melanogaster (33, 34), Caenorhabditis elegans (35) or Danio rerio (36, 37) offering 352 
advantages in terms of speed, cost, technical convenience and ethical acceptability over the 353 
mouse model. Except for the recent Drosophila model (34), these models have not been 354 
reported for antibiotic assessments against Mabs. We propose here the ZF model to 355 
visualize, by non-invasive imaging, the progressive infection of Mabs in live animals, and to 356 
quantifying the effect of drug treatment. We successfully investigated the suitability and 357 
sensitivity of two clinically relevant drugs, clarithromycin and imipenem, to visualize in a 358 
dose- and time-dependent manner the dynamics of cord and abscess formation/resorption. 359 
One major advantage of this model, compared to mice, is the ease and rapidity of 360 
experimentation within a restricted time scale and low cost. That both drugs had a positive 361 
impact in terms of embryo survival was correlated to a significant reduction in the number of 362 
CFU and abscesses, demonstrating a proof of concept that ZF embryos are suitable for drug 363 
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efficacy testing. Since in vitro studies demonstrated decreased MICs in the presence of 364 
imipenem, for clarithromycin, minocycline, levofloxacin and moxifloxacin (38), future work 365 
should also address the in vivo efficacy of these drug combinations using the Mabs/ZF 366 
couple.   367 
It is, however, noteworthy that despite their unique features for in vivo drug testing, ZF 368 
embryos also present several disadvantages over mammalian models. In particular, there are 369 
some important anatomical differences between ZF embryos and mammals such as gills 370 
instead of lungs, hematopoiesis occurring in the anterior kidney instead of the bone marrow, 371 
lack of discernable lymph nodes as well as a very different reproductive system. The natural 372 
lack of adaptive immunity early in the development is very likely to affect the outcome of 373 
the infection, thus making it difficult to directly correlating data obtained in ZF and in 374 
humans. In addition, as shown in this study, embryos are adapted to testing antibiotics 375 
during acute R-Mabs infections but not during the chronic stages of the disease, which can 376 
be better modelled for instance using immuno-compromized mice (15). Since 377 
pharmacokinetics are not known in ZF, it remains difficult at this stage to directly transpose 378 
the MIC data obtained in ZF to humans. As a consequence, this biological system should 379 
essentially be regarded as an early model for pre-clinical drug testing and/or to select new 380 
active compounds which should then be evaluated in other models before clinical trials.  381 
The perspectives of application of the present findings are multiple. First, this method 382 
could be implemented to address the in vivo drug susceptibility profiles of clinical isolates 383 
including strains from CF and non-CF patients, as Mabs clinical strains are not uniformly 384 
susceptible to currently used antibiotics. Due to these strain-to-strain variations (17, 39), no 385 
optimal regimen has been established to cure Mabs infections and determining the 386 
susceptibility/resistance profile of clinical strains may greatly help the clinician to select 387 
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optimal drug treatments. It is worth mentioning that for this particular application, no 388 
absolute requirement for the tested strains to carry pTEC27 is needed, as visualization of 389 
fluorescent bacteria is not necessary if only assessing ZF survival. Second, since the ZF is 390 
particularly amenable to mimic a CF-like micro-environment, by silencing the cftr expression 391 
level (40), this system could be used to compare the therapeutic efficacy of clarithromycin 392 
and imipenem (and perhaps other antibiotics) in a cftr-deficient environment as it remains to 393 
be established whether a defect in CFTR affects susceptibility to drugs. Third, this method 394 
could be further exploited to compare the intrinsic activity of antibiotics in vivo in embryos 395 
infected with the three species of the M. abscessus complex - M. abscessus sensu stricto, M. 396 
massiliense, and M. bolletii - which are known to respond differently to antibiotics in vitro 397 
(41, 42).  398 
Finally, the ZF embryo is particularly suited for high throughput screening as shown 399 
recently for M. marinum (36, 43, 44). Work is currently in progress in our laboratory to 400 
develop an in vivo platform for high-throughput screening of molecules against Mabs in order 401 
to speed up the process of identifying promising drug candidates, particularly warranted due 402 
to the extreme resistance of Mabs to most current antibiotics. 403 
404 
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FIGURE LEGENDS 551 
 552 
Figure 1. Kinetics of colonization of M. abscessus in aerosolised or intravenously infected 553 
BALB/c mice. (A) Mice were aerosolized by 4 × 10
7
 CFU/ml of R-Mabs. Animal were then 554 
sacrificed at days 1, 3, 8, 27 prior to CFU counting in the liver, spleen and lungs. Results are 555 
expressed as the log units of CFU. (B) Mice were challenged i.v. 10
6
 CFU of R-Mabs. Animals 556 
were then sacrificed at days 1, 15 and 30 to determine the CFU counts in the different 557 
organs. Results are expressed as mean Log10 CFU from 2-3 independent experiments (n=5-7 558 
mice for each time point). Error bars represent the standard error of the mean (SEM). 559 
 560 
Figure 2. Experimental protocol to assess the in vivo drug activity on M. abscessus 561 
infection. ZF embryos were i.v. infected with у300 CFU of R-Mabs expressing tdTomato and 562 
distributed and incubated into 96-wells plate (1). From 1dpi, embryos were exposed to the 563 
drugs of interest which were directly added to the wells. Drugs are then removed and daily 564 
renewed for 5 days (2). To determinate the in vivo antibacterial effects of the drugs, the 565 
embryo survival, the bacterial loads and the evolution of the infection process were 566 
monitored at a spatiotemporal level by videomicroscopy (3).  567 
 568 
Figure 3. In vivo characterization of clarithromycin activity on M. abscessus infection. (A-F) 569 
Embryos were soaked in clarithromycin at 1.7X, 17X or 170X the MIC for 5 days. The red bar 570 
indicates the start and duration of treatment. (A) Survival of uninfected embryos treated 571 
with various doses of clarithromycin and compared to mock controls (DMSO 1%) (n=20 for 572 
each, representative of three independent experiments). Representative microscopy image 573 
of an untreated (inset, upper panel) or drug treated-embryo (inset, lower panel) at 8dpf. 574 
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Clarithromycin appears toxic at the highest concentration as evidenced by the development 575 
of abnormalities and the increased mortality rate in the drug-exposed embryos compared to 576 
the mock control (p=0.028, log-rank test). (B) Survival of infected Mabs treated at various 577 
doses of clarithromycin and compared to untreated infected embryos (у300 CFU, n=20, 578 
representative of three independent experiments). A significant increased survival was 579 
observed in the infected-embryos exposed to the highest drug concentration (p=0.029, log-580 
rank test). (C) Bacterial loads of untreated or treated-embryos (у400 CFU). Results are 581 
expressed as mean Log10 CFU per embryo from three independent experiments. A significant 582 
reduction in bacterial burdens with 170X the MIC in drug treated-embryos is observed at 583 
5dpi. (D) Spatiotemporal visualization of the infection by Mabs expressing dtTomato (у300 584 
CFU) in untreated or drug treated-embryos. The representative fluorescence and 585 
transmission overlay of whole embryos are shown. The yolk is auto-fluorescent. (E) 586 
Frequency of abscesses in whole untreated or drug treated-embryos over 13dpi (у300 CFU; 587 
average of three independent experiments). Infected embryos developed significantly less 588 
abscesses in the presence of clarithromycin at 170X the MIC than untreated infected-589 
embryos. (F) Average localization of abscesses of the infected embryos in (E). Mabs-infected 590 
ZF developed significantly less abscesses within the brain and the spinal when exposed to 591 
the highest clarithromycin dose as compared to untreated infected-ZF. For (C) statistics were 592 
calculated using one-way ANOVA or for (E) and (F) with Fishers exact test comparing each 593 
category of drug-treated embryos to untreated control. Error bars represent the SEM. 594 
**p<0.01. 595 
 596 
Figure 4. Imipenem treatment cures M. abscessus-infected embryos. (A-E) From 1dpi, 597 
embryos were exposed for 5 days to imipenem concentrations corresponding to 0.5X, 5X or 598 
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28X the MIC. (A) Survival of infected R-Mabs embryos treated at various doses of imipenem 599 
and compared to untreated infected embryos (у300 CFU, n=20, representative of three 600 
independent experiments). Survival of treated R-Mabs infected embryos is dose-dependent. 601 
Significant increased survival was observed in infected-embryos exposed to 5 X and 28X MIC 602 
of imipenem. The red bar indicates the start and duration of treatment. (B) Bacterial loads of 603 
untreated or imipenem treated-embryos (у400 CFU). Results are expressed as mean Log10 604 
CFU per embryo from three independent experiments. A significant decreased of bacterial 605 
load is already observed after 3dpi in the 28X MIC imipenem treated-embryos. (C) 606 
Spatiotemporal visualization of the infection by R-Mabs expressing tdTomato (у300 CFU) in 607 
untreated or imipenem treated-embryos. The representative fluorescence and transmission 608 
overlay of whole embryos are shown. (D) Frequency of abscesses in whole untreated or 609 
imipenem-treated embryos over 13dpi (у300 CFU, average of three independent 610 
experiments). Only the 28X MIC imipenem treated-embryos developed significantly fewer 611 
abscesses than untreated infected-embryos. (E) Average localization of abscesses of the 612 
infected embryos in (D). 5X and 28X MIC of imipenem treated-embryos infected by Mabs 613 
developed fewer abscesses within the brain than untreated infected-embryos. For (B) 614 
statistics were calculated using one-way ANOVA or for (D) and (E) with Fishers exact test 615 
comparing each category of imipenem-treated embryos to untreated control. Error bars 616 
represent the SEM. *p=0.02, **p<0.01, ***p<0.001. 617 
 618 
Figure 5. Imipenem treatment decreases the early pathophysiological signs within the CNS. 619 
(A-D). tdTomato-expressing R-Mabs (у300 CFU) are injected in 30hpf embryos (n=15, 620 
average of three independent experiments). From 1dpi, embryos were exposed to imipenem 621 
at 0.5X, 5X or 28X MIC during 5 days. (A) Fluorescence microscopy of a typical R serpentine 622 
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cord. Scale bar, 100ʅm. (B) Fluorescence and DIC overlay of whole heads of a 28X MIC 623 
imipenem-treated and untreated infected embryos with fluorescent R-Mabs showing 624 
serpentine cord (white arrow). Scale bars, 100ʅm. (C) Percentage of embryos with cords in 625 
whole untreated and imipenem-treated embryos at 4dpi. A significant reduction in the 626 
proportion of embryos with cords was observed when embryos were treated with the 627 
highest (28X MIC) imipenem concentration. (D) Average localization of cord within the 628 
infected embryos in (C). Infected embryos treated with the intermediate (5X MIC) and high 629 
(28X MIC) imipenem doses developed significantly fewer serpentine cords within the CNS 630 
compared to untreated infected-embryos. For (C) and (D), statistics were calculated using 631 
Fishers exact test comparing each category of imipenem-treated embryos to untreated 632 
control. All results are expressed as the average from three independent experiments and 633 
error bars represent the SEM. 634 
 635 
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Figure 1. Kinetics of colonization of M. abscessus in aerosolised or intravenously infected BALB/c mice. (A) Mice were
aerosolized by 4 × 107 CFU/ml of R-Mabs. Animal were then sacrificed at days 1, 3, 8, 27 prior to CFU counting in the liver,
spleen and lungs. Results are expressed as the log units of CFU. (B)Mice were challenged i.v. 106 CFU of R-Mabs. Animals
were then sacrificed at days 1, 15 and 30 to determine the CFU counts in the different organs. Results are expressed as
mean Log10 CFU from 2-3 independent experiments (n=5-7 mice for each time point). Error bars represent the standard
f th (SEM)error o e mean .
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Figure 2. Experimental protocol to assess the in vivo drug activity on M. abscessus infection. ZF embryos were i.v.
infected with у300 CFU of R-Mabs expressing tdTomato and distributed and incubated into 96-wells plate (1). From 1dpi,
embryos were exposed to the drugs of interest which were directly added to the wells. Drugs are then removed and daily
d f 5 d (2) T d i h i i ib i l ff f h d h b i l h b i lrenewe or ays . o eterm nate t e n v vo ant acter a e ects o t e rugs, t e em ryo surv va , t e acter a
loads and the evolution of the infection process were monitored at a spatiotemporal level by videomicroscopy (3).
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Figure 3. In vivo characterization of clarithromycin activity onM. abscessus infection. (A-F) Embryos were soaked in clarithromycin at
1.7X, 17X or 170X the MIC for 5 days. The red bar indicates the start and duration of treatment. (A) Survival of uninfected embryos
treated with various doses of clarithromycin and compared to mock controls (DMSO 1%) (n=20 for each, representative of three
independent experiments). Representative microscopy image of an untreated (inset, upper panel) or drug treated-embryo (inset, lower
l) 8d f Cl i h i i h hi h i id d b h d l f b li i d h
0%
UNT MIC 1.7X MIC 17X MIC 170X
0%
UNT MIC 1.7X MIC 17X MIC 170X
pane at p . ar t romyc n appears tox c at t e g est concentrat on as ev ence y t e eve opment o a norma t es an t e
increased mortality rate in the drug-exposed embryos compared to the mock control (p=0.028, log-rank test). (B) Survival of infected
Mabs treated at various doses of clarithromycin and compared to untreated infected embryos (у300 CFU, n=20, representative of three
independent experiments). A significant increased survival was observed in the infected-embryos exposed to the highest drug
concentration (p=0.029, log-rank test). (C) Bacterial loads of untreated or treated-embryos (у400 CFU). Results are expressed as mean
Log10 CFU per embryo from three independent experiments. A significant reduction in bacterial burdens with 170X the MIC in drug
treated-embryos is observed at 5dpi. (D) Spatiotemporal visualization of the infection by Mabs expressing dtTomato (у300 CFU) in
untreated or drug treated-embryos. The representative fluorescence and transmission overlay of whole embryos are shown. The yolk is
auto-fluorescent (E) Frequency of abscesses in whole untreated or drug treated-embryos over 13dpi (у300 CFU; average of three.
independent experiments). Infected embryos developed significantly less abscesses in the presence of clarithromycin at 170X the MIC
than untreated infected-embryos. (F) Average localization of abscesses of the infected embryos in (E). Mabs-infected ZF developed
significantly less abscesses within the brain and the spinal when exposed to the highest clarithromycin dose as compared to untreated
infected-ZF. For (C) statistics were calculated using one-way ANOVA or for (E) and (F) with Fishers exact test comparing each category
of drug-treated embryos to untreated control. Error bars represent the SEM. **p<0.01.
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Figure 4. Imipenem treatment cures M. abscessus-infected embryos. (A-E) From 1dpi, embryos were exposed for 5 days
to imipenem concentrations corresponding to 0.5X, 5X or 28X the MIC. (A) Survival of infected R-Mabs embryos treated
at various doses of imipenem and compared to untreated infected embryos (у300 CFU, n=20, representative of three
0%
UNT MIC 0.5X MIC 5X MIC 28X
E
m
b
0%
UNT MIC 0.5X MIC 5X MIC 28X
E
m
b
independent experiments). Survival of treated R-Mabs infected embryos is dose-dependent. Significant increased survival
was observed in infected-embryos exposed to 5 X and 28X MIC of imipenem. The red bar indicates the start and duration
of treatment. (B) Bacterial loads of untreated or imipenem treated-embryos (у400 CFU). Results are expressed as mean
Log10 CFU per embryo from three independent experiments. A significant decreased of bacterial load is already observed
after 3dpi in the 28X MIC imipenem treated-embryos. (C) Spatiotemporal visualization of the infection by R-Mabs
expressing tdTomato (у300 CFU) in untreated or imipenem treated-embryos. The representative fluorescence and
transmission overlay of whole embryos are shown. (D) Frequency of abscesses in whole untreated or imipenem-treated
embr os o er 13dpi ( 300 CFU a erage of three independent e periments) Onl the 28X MIC imipenem treatedy v у , v x . y -
embryos developed significantly fewer abscesses than untreated infected-embryos. (E) Average localization of abscesses
of the infected embryos in (D). 5X and 28X MIC of imipenem treated-embryos infected by Mabs developed fewer
abscesses within the brain than untreated infected-embryos. For (B) statistics were calculated using one-way ANOVA or
for (D) and (E) with Fishers exact test comparing each category of imipenem-treated embryos to untreated control. Error
bars represent the SEM. *p=0.02, **p<0.01, ***p<0.001.
 o
n
 August 8, 2019 at PERIO
DICALS O
FFICE, M
AIN LIBRARY, UNIVERSITY O
F SHEFFIELD
http://aac.asm
.org/
D
ow
nloaded from
 
A B
MIC 28XInf UNT
***
*
R cord
**
C D
75%
100%
co
rd
s
75%
100%
co
rd
s
SNC vasculature
0%
25%
50%
UNT MIC 0 5X MIC 5X MIC 28X
E
m
b
ry
o
s 
w
it
h
 
0%
25%
50%
UNT MIC 0 5X MIC 5X MIC 28X
E
m
b
r
y
o
s 
w
it
h
 c
Figure 5. Imipenem treatment decreases the early pathophysiological signs within the CNS. (A-D). tdTomato-expressing
R Mabs (у300 CFU) are injected in 30hpf embryos (n=15 average of three independent experiments) From 1dpi
 .    .   
- , . ,
embryos were exposed to imipenem at 0.5X, 5X or 28X MIC during 5 days. (A) Fluorescence microscopy of a typical R
serpentine cord. Scale bar, 100ʅm. (B) Fluorescence and DIC overlay of whole heads of a 28X MIC imipenem-treated and
untreated infected embryos with fluorescent R-Mabs showing serpentine cord (white arrow). Scale bars, 100ʅm. (C)
Percentage of embryos with cords in whole untreated and imipenem-treated embryos at 4dpi. A significant reduction in
the proportion of embryos with cords was observed when embryos were treated with the highest (28X MIC) imipenem
concentration. (D) Average localization of cord within the infected embryos in (C). Infected embryos treated with the
intermediate (5X MIC) and high (28X MIC) imipenem doses developed significantly fewer serpentine cords within the CNS
compared to untreated infected-embryos. For (C) and (D), statistics were calculated using Fishers exact test comparing
each category of imipenem-treated embryos to untreated control. All results are expressed as the average from three
independent experiments and error bars represent the SEM.
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